Page last updated: 2024-09-04

canertinib and metoprolol

canertinib has been researched along with metoprolol in 1 studies

Compound Research Comparison

Studies
(canertinib)
Trials
(canertinib)
Recent Studies (post-2010)
(canertinib)
Studies
(metoprolol)
Trials
(metoprolol)
Recent Studies (post-2010) (metoprolol)
1249655,8211,7431,304

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)metoprolol (IC50)
Beta-2 adrenergic receptorHomo sapiens (human)2.573
Beta-1 adrenergic receptorHomo sapiens (human)0.176
Cytochrome P450 2C9 Homo sapiens (human)4.87
Cytochrome P450 2J2Homo sapiens (human)4.87

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chan, OH; Denny, WA; Elliott, WL; Greis, KD; Lipka, E; Loo, JA; Rewcastle, GW; Reyner, EL; Showalter, HD; Smaill, JB; Vincent, PW1

Other Studies

1 other study(ies) available for canertinib and metoprolol

ArticleYear
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
    Journal of medicinal chemistry, 2000, Apr-06, Volume: 43, Issue:7

    Topics: Acrylamides; Animals; Antineoplastic Agents; Biological Transport; Caco-2 Cells; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Humans; Mice; Mice, Nude; Morpholines; Neoplasm Transplantation; Phosphorylation; Pyrimidines; Quinazolines; Receptor, ErbB-2; Solubility; Spectrometry, Mass, Electrospray Ionization; Transplantation, Heterologous; Tumor Cells, Cultured

2000